Recent Updates
Recently added Catalysts

Follitropin alfa liquid formulation

Phase 4FDA approved 2004

Infertility | Small molecule | Other |Merck KGaA|Trials Updated: May 28, 2021

Follitropin alfa liquid formulation development status

FDA approval Mar 25, 2004 as Gonal-F
Approval holderEmd Serono
ApplicationBLA021765
Highest phase Phase 4 (NCT01871532)
Phase scored for MKGAFPhase 3
Registered trials 10 across 3 sponsors since Nov 2005

Follitropin alfa liquid formulation target and mechanism

ModalitySmall molecule

Also known as Gonal-f

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

RandomizedACTIVE_CONTROLLED
Total Trials3
Total Enrollment451

FDA Designations

No designations recorded

Follitropin alfa liquid formulation clinical trials

Follitropin alfa liquid formulation · 3 trials · 5 indications

Phase 3 3
NCT01297465PERgoveriS In Stratified Treatment for Assisted Reproductive TechniqueAssisted Reproductive Techniques
COMPLETED202 Analytics
NCT01183143Convenience and Safety of Assisted Reproductive Technology Procedures Using a Gonal-F Filled by Mass (Fbm) Liquid Formulation Applied by Pen for Ovulation Induction and In-vitro FertilizationInfertility
COMPLETED215 Analytics
NCT01081639To Evaluate the Convenience, Safety and Efficacy of Follitropin Alfa Liquid Pen Compared With Follitropin Beta Liquid PenInfertility
COMPLETED34 Analytics
PHASE3COMPLETED
PERgoveriS In Stratified Treatment for Assisted Reproductive Technique
Assisted Reproductive TechniquesUnlock trial analytics
PHASE3COMPLETED
Convenience and Safety of Assisted Reproductive Technology Procedures Using a Gonal-F Filled by Mass (Fbm) Liquid Formulation Applied by Pen for Ovulation Induction and In-vitro Fertilization
InfertilityUnlock trial analytics
PHASE3COMPLETED
To Evaluate the Convenience, Safety and Efficacy of Follitropin Alfa Liquid Pen Compared With Follitropin Beta Liquid Pen
InfertilityUnlock trial analytics

Study Endpoints

Primary Endpoints

Total Number of Oocytes Retrieved
OPU day (34-38 hours post r-hCG day [end of stimulation cycle {approximately 11 days}])

The total number of oocytes retrieved per reporting group on the day of ovum pick-up (OPU) (34-38 hours post r-hCG day) was calculated. Oocyte retrieval is a technique used in in-vitro fertilization (IVF) in order to remove oocytes from the ovary of the female participant, enabling fertilization outside the body.

Number of Subjects Who Self-administered the Investigational Medicinal Product (IMP)
Up to 1 year

Number of subjects who self-administered the IMP were presented in this outcome measure.

Convenience and Safety
1 year

Convenience parameters included nurse/subjects preference; time to train subject; operative tolerance and wastage of product which were assessed during the post-treatment period. Safety parameters included local reactions (pain, bruising, redness, itching, swelling)and adverse drug events which were assessed during the pre-treatment, treatment and post-treatment period.

Secondary Endpoints

Total Dose and Mean Daily Dose of Follicle Stimulating Hormone (FSH)
Day 1 up to r-hCG day (end of stimulation cycle [approximately 11 days])
Total Number of Stimulation Treatment Days
Day 1 up to r-hCG day (end of stimulation cycle [approximately 11 days])
Implantation Rate
Days 35-42 post r-hCG day (end of stimulation cycle [approximately 11 days])
Unlock Study Endpoints

Study Design & Arms

AllocationRANDOMIZED
MaskingNONE
ModelPARALLEL
PurposeTREATMENT

Treatment Arms

ArmTypeDescription
Gonal-f® Plus Pergoveris®ACTIVE_COMPARATOR -
Pergoveris®EXPERIMENTAL -
GONAL-f®EXPERIMENTAL -
Gonal-fEXPERIMENTAL -
PuregonACTIVE_COMPARATOR -

Interventions

NameTypeDescription
Gonal-f®DRUGGonal-f® (follitropin alfa) 300 International Unit (IU) will be administered subcutaneously once daily from stimulation day 1 (S1) to stimulation day 5 (S5).
Pergoveris®DRUGPergoveris® (follitropin alfa and lutropin alfa) 300 IU will be administered subcutaneously starting from S6 until recombinant human chorionic gonadotropin (r-hCG) administration day (at least 1 follicles \>= 18 mm). The dose of Pergoveris® was adjusted based upon the participant's ovarian response and according to the site's standard practice.
Recombinant human chorionic gonadotropin (r-hCG)DRUG250 microgram of r-hCG will be administered once subcutaneously on r-hCG day (at least 1 follicles \>= 18 mm).
Follitropin alfa liquid formulationDRUGFollitropin alfa (Gonal-f) liquid pen (300, 450 and 900 IU) was applied by subcutaneous (sc) administration. Regimen of recombinant FSH-stimulation followed the standard protocol of the IVF-center
Follitropin beta liquid formulationDRUGFollitropin beta (Puregon) liquid cartridge (300 and 600 IU) used with the Pen was applied by sc administration. Regimen of recombinant FSH-stimulation followed the standard protocol of the IVF-center
Unlock Study Design Details

Eligibility Criteria

Age Range36 Years to 40 Years
SexFEMALE
Healthy VolunteersNo
Study Sites23

Inclusion Criteria: * Be a female subject justifying an in vitro fertilization and embryo transfer (IVF/ET) treatment * Be between her 36th and 40th birthday (both included) at the time of the randomization visit * Have early follicular phase (Day 2-4) serum level of basal follicle stimulating horm...

Countries:DenmarkFinlandFranceGermanyGreeceItalyNetherlandsPolandRussiaSlovakiaUnited Kingdom
Unlock Eligibility Criteria